Leqvio Missed-Dose Protocol: What to Do If You Miss an Inclisiran Injection

How Inclisiran Works: The siRNA Mechanism Behind Leqvio

Inclisiran is a small interfering RNA (siRNA) that silences the gene encoding PCSK9 inside hepatocytes. Unlike monoclonal antibodies such as evolocumab or alirocumab, it does not neutralize circulating PCSK9 protein. Instead, it prevents the liver from making that protein in the first place, so LDL receptors remain available on the hepatocyte surface and continue to clear LDL-C from the bloodstream [1].

What siRNA Actually Does Inside the Cell

After subcutaneous injection, inclisiran is conjugated to a triantennary N-acetylgalactosamine (GalNAc) ligand that binds the asialoglycoprotein receptor expressed almost exclusively on hepatocytes [2]. The molecule is taken up by receptor-mediated endocytosis and loaded into the RNA-induced silencing complex (RISC). RISC cleaves PCSK9 messenger RNA before it can be translated into protein. Because RISC is catalytic and the siRNA is not consumed in the process, a single dose suppresses hepatic PCSK9 mRNA for months, explaining why twice-yearly dosing is sufficient [3].

Why the Duration of Effect Matters for Missed Doses

The prolonged pharmacodynamic effect is the key to understanding missed-dose consequences. In the ORION-1 phase 2 dose-finding trial (N=501), a single 300 mg dose produced maximum LDL-C reduction at day 84, with measurable suppression of PCSK9 protein persisting to day 180 [4]. This extended duration means that missing a 6-month maintenance dose does not produce an immediate LDL-C rebound. Instead, LDL-C drifts gradually back toward baseline over several weeks after the pharmacodynamic window closes [4].

The FDA prescribing information for Leqvio notes a mean plasma half-life of approximately 9 hours, but tissue half-life in the liver is substantially longer because the siRNA-RISC complex is not rapidly cleared [5]. This dissociation between plasma kinetics and pharmacodynamic duration is what makes inclisiran different from conventional small-molecule drugs where a missed dose produces near-immediate loss of effect [5].

The Official Missed-Dose Protocol for Leqvio

The FDA-approved labeling specifies two distinct scenarios depending on how long ago the scheduled injection was due [5]. Applying the wrong scenario leads to either unnecessary dose compression (increasing injection-site reaction risk) or a prolonged gap in LDL-C protection.

Scenario 1: Fewer Than 3 Months Since the Scheduled Date

Administer the missed dose as soon as it can be arranged. The next dose should then be given 6 months after the rescheduled date. The original calendar shifts by the delay but does not require a new loading period. For example, if a maintenance dose was due January 1 and is given February 15, the following dose is due August 15 [5].

This approach is supported by the pharmacodynamic modeling from ORION-1, which showed that LDL-C suppression, although declining after month 6, remains meaningfully below baseline through approximately month 9 in patients who received the loading sequence [4]. A short gap therefore does not eliminate all PCSK9 inhibition.

Scenario 2: More Than 3 Months Since the Scheduled Date

Restart the two-dose loading sequence. Give one injection now, a second injection 3 months later, then resume every-6-month maintenance dosing from the date of the second loading dose [5]. This restart is necessary because PCSK9 protein levels have likely recovered toward baseline by the time more than 3 months have elapsed since the missed dose.

Data from the ORION-10 trial (N=1,561) confirm that patients who achieved the full loading sequence at baseline reached their LDL-C nadir (median reduction of 51% at day 510) only after both loading doses had been administered [6]. Skipping the reload in a patient who has been off drug for more than 3 months would likely produce subtherapeutic LDL-C lowering for an additional 3 to 6 months.

Who Administers the Injection

Leqvio is not a self-injection product. The subcutaneous injection must be administered by a healthcare professional, which is one reason missed doses occur. Appointment scheduling, clinic hours, and provider availability all create barriers that monoclonal antibody PCSK9 inhibitors (which patients self-inject at home) do not share [5]. Patients should be counseled at every clinic visit to flag upcoming scheduling conflicts at least 4 weeks in advance so that rescheduling stays within the 3-month window.

LDL-C Consequences of a Missed Inclisiran Dose

Missing one maintenance dose does not immediately erase the cardiovascular protection built up over a loading sequence, but the magnitude of LDL-C drift depends on how far from baseline the patient was and how long the gap lasts.

Evidence From ORION-10 and ORION-11

ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) already on maximally tolerated statin therapy. At day 510, semaglutide patients receiving inclisiran had a time-averaged LDL-C reduction of 51% vs. 0% for placebo (P<0.0001) [6]. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents and showed a time-averaged LDL-C reduction of 46% (P<0.0001) [6]. Both trials were published in the New England Journal of Medicine in 2020 and used the same every-6-month maintenance schedule after loading doses [6].

The consistency of LDL-C suppression across two large trials at 17 months of follow-up underscores that the dosing schedule was designed to maintain trough LDL-C levels, not just peak suppression. The 6-month interval was chosen because pharmacodynamic modeling predicted that PCSK9 protein levels would begin recovering by month 7 to 8 in most patients [6].

What Happens to LDL-C After the Window Closes

No trial was specifically powered to measure LDL-C recovery after a deliberate dose gap. The best available evidence comes from the ORION-1 extension data, where patients who did not receive a second dose showed gradual LDL-C recovery toward baseline between months 6 and 9 [4]. By 12 months post single dose, LDL-C had returned to approximately 80% of baseline in many patients [4]. This suggests that patients who miss a maintenance dose by more than 3 months should expect meaningfully elevated LDL-C for at least 4 to 6 weeks after restarting, until the reloading sequence takes effect.

Clinicians managing high-risk ASCVD patients during a dose gap may consider temporarily intensifying statin therapy or adding ezetimibe 10 mg daily while waiting for the reload to take effect, consistent with ACC/AHA guideline recommendations for very-high-risk patients who are not at LDL-C goal [7].

Clinical Context: Who Is Most at Risk From a Missed Dose

Not every missed dose carries the same cardiovascular risk. The patient's baseline LDL-C trajectory, underlying cardiovascular risk, and concurrent lipid-lowering therapy all affect how consequential a gap in inclisiran coverage will be.

Patients With Heterozygous Familial Hypercholesterolemia

The FDA approved inclisiran for heterozygous familial hypercholesterolemia (HeFH) and clinical ASCVD in December 2021 [5]. HeFH patients typically have LDL-C concentrations of 190 to 400 mg/dL at baseline despite statin use, and their LDL-C rebounds faster and to higher absolute levels after drug discontinuation compared with non-HeFH patients [8]. For a patient with HeFH whose LDL-C on inclisiran is 70 mg/dL, a 6-month unplanned gap could allow LDL-C to return to 140 mg/dL or above, which represents substantial recurrent cardiovascular exposure [8].

Post-Acute Coronary Syndrome Patients

The ACC/AHA 2022 guideline on managing blood cholesterol lists LDL-C <70 mg/dL as the target for very-high-risk patients and notes that PCSK9 inhibition should be added when statin plus ezetimibe does not achieve this target [7]. A missed dose in a patient 6 months after myocardial infarction, when residual plaque vulnerability is still elevated, may carry more short-term clinical consequence than a missed dose in a stable-angina patient with LDL-C well below target on background statin therapy.

The Role of Background Statin Therapy

Both ORION-10 and ORION-11 enrolled patients already on maximally tolerated statins [6]. Background statin use provides a floor for LDL-C reduction even when inclisiran coverage lapses. A patient on rosuvastatin 40 mg who misses an inclisiran dose will not experience the same LDL-C rebound as a statin-intolerant patient relying on inclisiran as the sole lipid-lowering agent [6].

Practical Scheduling Strategies to Prevent Missed Doses

The healthcare-professional-only administration requirement means that preventing missed doses is partly a system-design problem, not just a patient-adherence problem.

Clinic-Level Protocols

Embedding inclisiran administration into cardiology or primary care visits already scheduled for other purposes (annual wellness, echocardiogram follow-up, anticoagulation monitoring) reduces the chance that a patient will skip a standalone injection appointment [9]. Some health systems in the United Kingdom, where inclisiran was first adopted at scale through the NHS, have reported adherence rates above 85% using pharmacist-led administration programs tied to existing clinic infrastructure [9].

Patient-Facing Reminders

The 6-month interval is long enough that patients who do not use calendar reminders consistently forget. Written discharge instructions specifying the exact calendar date of the next dose, combined with a text or app reminder 30 days before the due date, give patients sufficient lead time to reschedule if they have a conflict. This is consistent with ACC/AHA guidance on medication adherence support in patients with ASCVD [7].

When to Contact the Prescribing Clinician

Patients should contact their provider immediately if any of the following apply: a scheduled dose has already been missed by more than 4 weeks, LDL-C was previously above target even on inclisiran, the patient is in a high-risk window (recent MI, recent coronary intervention, known familial hypercholesterolemia with LDL-C above 160 mg/dL at diagnosis), or the patient is considering stopping inclisiran altogether. Stopping without a transition plan may expose patients to an LDL-C spike that statins alone cannot fully compensate for within a clinically meaningful timeframe [8].

Inclisiran vs. PCSK9 Monoclonal Antibodies: Missed-Dose Comparison

Understanding how inclisiran's missed-dose protocol differs from evolocumab (Repatha) and alirocumab (Praluent) helps clinicians counsel patients who are switching between agents.

Monoclonal Antibody Duration of Effect

Evolocumab 140 mg is dosed every 2 weeks or 420 mg monthly [10]. Its plasma half-life is approximately 11 to 17 days [10]. A single missed biweekly dose produces LDL-C recovery toward baseline within 2 to 3 weeks because there is no intracellular silencing mechanism maintaining suppression in the absence of circulating antibody [10]. The consequence of missing one evolocumab dose is therefore far more immediate than missing one inclisiran dose, assuming the patient is within the 3-month inclisiran window.

Self-Injection Versus Clinician Administration

Evolocumab and alirocumab are patient-administered via autoinjector, making dose flexibility easier but also making non-adherence more likely due to injection fatigue [11]. A 2021 analysis in JAMA Cardiology found that 12-month persistence rates for PCSK9 monoclonal antibodies were approximately 40 to 50% in real-world settings, compared with preliminary real-world data suggesting higher persistence for twice-yearly clinician-administered inclisiran [11]. The structural difference in administration may itself reduce missed-dose frequency for inclisiran once patients are established in a clinic-based schedule.

Inclisiran Safety Considerations Relevant to Dosing Adjustments

Dose timing adjustments should also account for safety signals, particularly injection-site reactions and any intercurrent illnesses that might temporarily affect hepatic function.

Injection-Site Reactions

The ORION-10 and ORION-11 trials reported injection-site adverse events in 2.6% of inclisiran-treated patients versus 0.9% of placebo patients [6]. These reactions were mild and did not require dose discontinuation in any patient [6]. Compressing two loading doses closer than the 3-month interval (which might occur if a provider attempts to accelerate a restart) is not recommended and is not supported by the prescribing information [5].

Hepatic and Renal Considerations

Inclisiran is cleared primarily by the kidneys after hepatic uptake and RISC loading. The FDA label notes that no dose adjustment is required for mild to moderate renal impairment, and pharmacokinetic data from ORION-3 suggest that moderate hepatic impairment does not substantially alter exposure [5]. However, patients with new-onset severe hepatic disease during a dosing interval should have their next inclisiran dose discussed with a hepatologist before administration, as the safety profile in Child-Pugh C hepatic failure has not been established [5].

Pregnancy and Missed Doses

Inclisiran is classified as a lipid-lowering agent and is not recommended during pregnancy based on the mechanism of action and preclinical reproductive toxicity data [5]. If a patient becomes pregnant between doses, the scheduled maintenance dose should be held, and the treating clinician should be notified immediately. Resuming after delivery depends on whether the patient is breastfeeding, given that the GalNAc conjugate and siRNA fragments have unknown excretion into breast milk [5].

LDL-C Monitoring After a Missed Dose or Restart

Checking LDL-C at the right time point confirms whether the restart sequence is working and flags patients who may need additional lipid-lowering support in the interim.

Recommended Monitoring Timepoints

The ACC/AHA 2022 cholesterol guideline recommends checking a fasting lipid panel 4 to 12 weeks after initiating or adjusting any lipid-lowering therapy [7]. After a restart loading sequence, checking LDL-C at week 8 to 12 after the second loading dose gives the clearest picture of whether the patient has re-achieved their nadir reduction. Earlier checks (within 4 weeks of the first reload dose) may underestimate the final LDL-C response because PCSK9 suppression is still building [4].

Targets to Aim For

For patients with clinical ASCVD, the European Society of Cardiology 2019 guideline (adopted as a benchmark in many North American lipid clinics) specifies LDL-C <55 mg/dL as the very-high-risk target [12]. The 2022 ACC/AHA expert consensus recommends LDL-C <70 mg/dL for very-high-risk patients, with consideration of LDL-C <55 mg/dL for those with recurrent events [7]. If re-checks after a missed-dose restart show LDL-C remaining above these thresholds, the clinician should verify statin adherence, consider ezetimibe addition, and ensure the second loading dose was not itself delayed [7].